Holen Sie sich die Stockscreener-App
0.78
5.01%
-0.0411
Schlusskurs vom Vortag:
$0.8211
Offen:
$0.7965
24-Stunden-Volumen:
392.84K
Relative Volume:
0.45
Marktkapitalisierung:
$8.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.23M
KGV:
-0.0524
EPS:
-14.8777
Netto-Cashflow:
$-15.31M
1W Leistung:
-1.02%
1M Leistung:
-23.53%
6M Leistung:
-73.10%
1J Leistung:
-94.33%
1-Tages-Spanne:
$0.7633
$0.8201
1-Wochen-Bereich:
$0.7401
$0.8599
52-Wochen-Spanne:
$0.7401
$55.00
Genprex Inc Stock (GNPX) Company Profile
Firmenname
Genprex Inc
Sektor
Branche
Telefon
512-537-7997
Adresse
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.78 | 8.69M | 0 | -16.23M | -15.31M | -14.88 |
VRTX
Vertex Pharmaceuticals Inc
|
437.20 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.92 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.45 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.78 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.25 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-26 | Eingeleitet | National Securities | Buy |
| 2019-04-29 | Eingeleitet | Noble Capital Markets | Outperform |
Genprex Inc Aktie (GNPX) Neueste Nachrichten
Genprex, Inc. Announces Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting - marketscreener.com
Genprex reports biomarker data from lung cancer gene therapy study - Investing.com
Genprex reports biomarker data from lung cancer gene therapy study By Investing.com - Investing.com Canada
Biomarker data link Trop-2 to PFS in Genprex (NASDAQ: GNPX) trials - Stock Titan
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting - PR Newswire
Genprex Inc. (GNPX) Edges Higher Amid Biotech Sector Cautious ToneLow Vol Factor - Newser
GNPX Should I Buy - Intellectia AI
Genprex (GNPX) Q1 2026 Earnings Stay the Course — EPS $-0.64Retail Trader Picks - Newser
Why Is Genprex, Inc. (GNPX) Stock Down Today? - Meyka
Genprex (GNPX) Showcases Promising Diabetes Gene Therapy Results - GuruFocus
Genprex, Inc. Files Form 8-K With SEC – Company Information and Filing Details for May 14, 2026 - Minichart
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting - BioSpace
Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy - TipRanks
Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT - TradingView
Genprex collaborators present diabetes gene therapy data - Investing.com
Genprex collaborators present diabetes gene therapy data By Investing.com - Investing.com UK
[8-K] Genprex, Inc. Reports Material Event - Stock Titan
Genprex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Genprex (NASDAQ: GNPX) raises cash through share sales amid going concern risk - Stock Titan
Genprex (GNPX) warrant holders report 249,788 shares, 2.69% stake - Stock Titan
Number of shareholders of Genprex Inc – LSE:0A8I - TradingView
GNPX (Genprex) Q1 loss narrower than expected, beating estimates by 37.8% despite zero revenue and shares ticking higher.Miss Estimates - newser.com
Top 3 Health Care Stocks That Are Set To Fly In Q2 - Benzinga
GNPX Forecast, Price Target & Analyst Ratings | GENPREX INC (NASDAQ:GNPX) - ChartMill
MSN Money - MSN
Genprex, Inc. Files Form 8-K With SEC: Company Information, Nasdaq Listing, and Regulatory Details - Minichart
Genprex Secures Patent for Reqorsa Gene Therapy in Cancer Treatm - GuruFocus
Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel - TipRanks
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer - BioSpace
Genprex | 8-K: Current report - Moomoo
Israel grants Genprex (NASDAQ: GNPX) patent for REQORSA lung cancer use - Stock Titan
Genprex (NASDAQ: GNPX) seeks approval for equity plan and reverse stock split - Stock Titan
Genprex collaborators to present diabetes gene therapy data at May meeting By Investing.com - Investing.com Australia
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting - BioSpace
Genprex collaborators to present diabetes gene therapy data at May meeting - Investing.com UK
average down - Moomoo
Genprex Highlights Promising Preclinical Data for Diabetes Gene Therapy - TipRanks
Genprex (GNPX) shows GPX-002 gene therapy reversed hyperglycemia in T2D mice - Stock Titan
Genprex biomarker research selected for ASCO 2026 meeting By Investing.com - Investing.com India
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting - StreetInsider
Genprex biomarker research selected for ASCO 2026 meeting - Investing.com
Lung cancer gene therapy study lands ASCO slot with biomarker data - Stock Titan
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy - The Malaysian Reserve
Genprex signs research deal to study lung cancer biomarkers By Investing.com - Investing.com India
Genprex (GNPX) Partners with MD Anderson for Cancer Research - GuruFocus
Finanzdaten der Genprex Inc-Aktie (GNPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):